A BILL to amend the Code of Virginia by adding in Chapter 1 of Title 32.1 an article numbered 3.1, consisting of sections numbered 32.1-23.8 through 32.1-23.13, relating to Independent Pharmacy Access and Resilience Pilot Program; report; sunset.
HB335 creates the Independent Pharmacy Access and Resilience Pilot Program within the Virginia Department of Health to improve pharmacy access in medically underserved areas and communities at risk of losing their local pharmacy. The program is designed to identify communities with limited access to pharmacy services, assess closure risks, and develop a planning report during fiscal year 2026-2027 using existing appropriated funds. It focuses on independent pharmacies rather than chain pharmacies and is intended to support sustainable pharmacy infrastructure, expanded clinical services, technology improvements, and partnerships with health systems, federally qualified health centers, health departments, and academic institutions.
If funded, the pilot would allow up to 12 independent pharmacies to participate voluntarily and receive technical assistance, workflow and revenue-cycle support, technology integration, capped stabilization grants, and help accessing alternative funding sources. The Department would prioritize pharmacies serving medically underserved, economically vulnerable, or high-need populations, including those participating in Medicaid, FAMIS, Medicare Part D, or other safety-net programs. The bill also requires evaluation of outcomes such as medication adherence, emergency department use, avoidable hospitalizations, vaccination access, workforce stability, and potential cost avoidance, with interim and final reports due in 2028 and 2029. The entire act would expire on July 1, 2030.
The bill’s impact on state law is to add a new article to Title 32.1 establishing a temporary pilot program and reporting framework, while expressly limiting its legal effects. It does not create an entitlement to funding, does not mandate insurers or pharmacy benefit managers, does not change licensure authority, and does not create liability for pharmacy closures. Implementation depends on a specific appropriation or secured nongeneral funds, and the Department is directed to seek nongeneral funds first before requesting general fund support.
Overall sentiment appears supportive of strengthening independent pharmacy access, especially in underserved and rural or economically vulnerable communities, but the bill’s structure reflects caution about cost and scope. The absence of recorded votes or committee transcripts suggests no documented floor debate in the available materials, and the bill was left in the House Appropriations Committee. That status, along with the funding contingency and narrow pilot design, indicates likely concern about fiscal impact and whether the program should proceed only if outside or dedicated funding is available.
The main points of contention are likely to be funding, program size, and whether state government should intervene in pharmacy market stability. The bill limits participation to 12 pharmacies, requires evaluation before any expansion, and avoids imposing obligations on insurers or pharmacy benefit managers, which suggests an effort to address concerns from fiscal and industry stakeholders. Supporters would likely emphasize access to care, medication adherence, and preventing pharmacy closures, while skeptics may question whether the pilot is too limited, too expensive, or insufficient to address broader structural problems in pharmacy reimbursement and workforce stability.
HB335 would add a new temporary pilot program to the Virginia Code under Title 32.1, authorizing the Department of Health to identify pharmacy-desert and medically underserved communities, select up to 12 independent pharmacies for support, and provide technical assistance, limited stabilization grants, and partnership-building resources. It also authorizes the Department to accept federal, charitable, and other nongeneral funds, requires interim and final reports to the Governor and General Assembly, and sunsets the act on July 1, 2030. The bill expressly avoids changing insurer, PBM, or licensure law and does not create a funding entitlement or liability for pharmacy closures.
The available context suggests generally favorable policy intent toward preserving independent pharmacies and improving access to medications and clinical services in underserved communities. At the same time, the bill’s placement in Appropriations and its contingent funding structure indicate caution about fiscal exposure and program feasibility. No committee transcripts or votes are available, so there is no recorded public debate in the provided materials, but the bill’s design reflects an attempt to balance access goals with budgetary restraint.
Likely areas of contention include whether the state should fund a targeted pharmacy stabilization pilot, whether support should be limited to only 12 independent pharmacies, and whether the program can meaningfully address pharmacy closures without broader reimbursement reform. Supporters are likely independent pharmacies, public health advocates, and community health organizations focused on access in underserved areas. Potential skeptics may include fiscal conservatives and stakeholders concerned about state spending, as well as parties who might prefer changes to pharmacy benefit manager or insurer practices rather than a limited pilot. The bill’s explicit disclaimer that it does not regulate insurers or PBMs suggests those issues were sensitive enough to warrant clarification.